Seattle biotech startup led by Fred Hutch, Adaptive vets raises $16M for rapid drug development tech
Investment into the Seattle biotech scene continues as Lumen Bioscience announced it received $16 million in Series B funding. The startup, led by former Adaptive and Fred Hutch employees, has patented technology that uses spirulina to deliver therapeutic proteins to treat and prevent highly prevalent diseases. The funds will help Lumen continue to the support this novel approach to rapid and low-cost drug development.